Paul Ivsin

Clinical trials should be simpler for both patients and sponsors. Trialmed brings a patient first approach to research by combining a global site network with flexible solutions that improve recruitment engagement and retention. By reducing barriers through digital tools and bringing studies closer to patients Trialmed helps drive more inclusive participation and stronger outcomes. Better trials start with a better experience for every patient.

Guest Column | May 27, 2026 By Paul Ivsin Both of these things are true: FDA guidance on clinical trial recruitment specifies that “Advertisements may state that subjects will be paid, but should not emphasize the payment or the amount to be paid, by such means as larger or bold type.” Many clinical trial ads routinely emphasize payment in larger and bold type. What is the cause of this? Scofflaws running amok in pharma?

What’s the real impact of the "one-and-done PI" in clinical trials? Some say it’s a major issue, while others question if it’s a concern at all. Clinical Leader Live’s expert panel—backed by research—dives into the data, debate, and potential solutions.